{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:27:02Z","timestamp":1788863222513,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":367,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Lessons Learned<\/jats:title>\n                    <jats:p>Apatinib has potential as an effective and safe second-line or higher treatment for patients with chemotherapy-refractory esophageal squamous cell carcinoma (ESCC). Clinical safety is of potential concern when administering apatinib to patients with uncontrolled esophageal lesions or severe invasion of trachea, bronchi, or major blood vessels. To the best of the authors' knowledge, this is the first prospective phase II study to investigate apatinib for patients with chemotherapy-refractory ESCC. Apatinib could provide an alternative option for ESCC after first-line or higher therapy in carefully selected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the efficacy and adverse effects of the oral vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor apatinib in patients with chemotherapy-refractory esophageal squamous cell carcinoma (ESCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled patients with chemotherapy-refractory ESCC. All patients received continuous apatinib 500 mg once daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between July 2017 and August 2018, 40 patients were recruited, of whom 5 (12.5%) had uncontrolled primary tumors. Additionally, three patients with partial response (PR) and 23 with stable disease (SD) were observed for overall response rate (ORR) of 7.5% and disease control rate (DCR) of 65.0%. Median progression-free survival (PFS) was 3.8 months (95% confidence interval [CI], 2.2\u20135.4); median overall survival (OS) was 5.8 months (95% CI, 3.2\u20138.4). Common adverse effects were fatigue (15%), hypertension (12.5%), and palmar-plantar erythrodysesthesia syndrome (10%). Two cases of death from massive bronchopulmonary hemorrhage were observed, and esophageal fistula occurred in another two patients. Notably, both patients with esophageal fistula and one patient with massive fatal bronchopulmonary hemorrhage were individuals with uncontrolled primary tumors (3\/5, 60%). Fatal bronchopulmonary hemorrhage in a second patient was associated with major blood vessel invasion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Apatinib has potential as an effective and safe treatment for patients with chemotherapy-refractory ESCC whose primary tumors are controlled and without severe invasion of trachea, bronchi, or major blood vessels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13668","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T01:43:15Z","timestamp":1609724595000},"page":"e925-e935","source":"Crossref","is-referenced-by-count":34,"title":["A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11)"],"prefix":"10.1093","volume":"26","author":[{"given":"Li","family":"Chu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[{"name":"Department\u2009of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashan","family":"Ai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhan","family":"Nie","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cancer Biology & Xijing Hospital of Digest Diseases, Fourth Military Medical University, Xi'an, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2874","authenticated-orcid":false,"given":"Kuaile","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"},{"name":"Department\u2009of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"2022020821443748700_onco13668-bib-0001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2022020821443748700_onco13668-bib-0002","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","article-title":"Epidemiology of esophageal squamous cell carcinoma","volume":"154","author":"Abnet","year":"2018","journal-title":"Gastroenterology"},{"key":"2022020821443748700_onco13668-bib-0003","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/1759-7714.12323","article-title":"Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma","volume":"7","author":"Wang","year":"2016","journal-title":"Thoracic Cancer"},{"key":"2022020821443748700_onco13668-bib-0004","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdp069","article-title":"Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"20","author":"Lorenzen","year":"2009","journal-title":"Ann Oncol"},{"key":"2022020821443748700_onco13668-bib-0005","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jnci\/86.14.1086","article-title":"Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus","volume":"86","author":"Ajani","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"2022020821443748700_onco13668-bib-0006","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40880-019-0359-7","article-title":"Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): A prospective randomized, multicenter, open-labeled phase 3 trial","volume":"39","author":"Huang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"2022020821443748700_onco13668-bib-0007","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00280-016-3179-3","article-title":"Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane","volume":"78","author":"Nomura","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022020821443748700_onco13668-bib-0008","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00280-014-2597-3","article-title":"A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy","volume":"74","author":"Shirakawa","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022020821443748700_onco13668-bib-0009","first-page":"2845","article-title":"A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer","volume":"27","author":"Burkart","year":"2007","journal-title":"Anticancer Res"},{"key":"2022020821443748700_onco13668-bib-0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/sj.bjc.6601168","article-title":"Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer","volume":"89","author":"Lordick","year":"2003","journal-title":"Br J Cancer"},{"key":"2022020821443748700_onco13668-bib-0011","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13014-015-0358-z","article-title":"Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy","volume":"10","author":"Zhou","year":"2015","journal-title":"Radiat Oncol"},{"key":"2022020821443748700_onco13668-bib-0012","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3857\/roj.2012.30.4.182","article-title":"Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy","volume":"30","author":"Kim","year":"2012","journal-title":"Radiat Oncol J"},{"key":"2022020821443748700_onco13668-bib-0013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.21037\/cco.2017.07.06","article-title":"Systemic therapy for esophageal cancer: Chemotherapy","volume":"6","author":"Ku","year":"2017","journal-title":"Chin Clin Oncol"},{"key":"2022020821443748700_onco13668-bib-0014","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"KEYNOTE-181 Investigators. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022020821443748700_onco13668-bib-0015","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"2022020821443748700_onco13668-bib-0016","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022020821443748700_onco13668-bib-0017","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy- refractory advanced or metastatic adenocarcinoma of the stomach or gastoesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022020821443748700_onco13668-bib-0018","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2147\/OTT.S150555","article-title":"Fatal hemoptysis in patients with advanced esophageal cancer treated with apatinib","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13668","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13668","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/e925\/42375491\/oncolo_26_6_e925.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/e925\/42375491\/oncolo_26_6_e925.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T16:53:12Z","timestamp":1644339192000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/6\/e925\/6520938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,2,1]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13668","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,2,1]]}}}